1 September 2020 in Cell Reports
DNA replication initiates from multiple origins, and selective CDC7 kinase inhibitors (CDC7is) restrain cell proliferation by limiting origin firing. We have performed a CRISPR-Cas9 genome-wide screen to identify genes that, when lost, promote the proliferation of cells treated with sub-efficacious doses of a CDC7i. We have found that the loss of function of ETAA1, an ATR activator, and RIF1 reduce the sensitivity to CDC7is by allowing DNA synthesis to occur more efficiently, notably during late S phase. We show that partial CDC7 inhibition induces ATR mainly through ETAA1, and that if ATR is subsequently inhibited, origin firing is unleashed in a CDK- and CDC7-dependent manner. Cells are then driven into a premature and highly defective mitosis, a phenotype that can be recapitulated by ETAA1 and TOPBP1 co-depletion. This work defines how ATR mediates the effects of CDC7 inhibition, establishing the framework to understand how the origin firing checkpoint functions.
15 December 2025 in Nature Communications
Drug combinations are essential to modern medicine, but their discovery remains slow and inefficient as experimental complexity expands rapidly with each additional drug tested. Although modern liquid handling systems enable complex and highly customizable experimental designs, a lack of strategies integrating these technologies with combination-specific analytical methods has limited throughput. Here we introduce Combocat, an open-source and streamlined framework that combines acoustic liquid handling protocols with machine learning-based inference to achieve ultrahigh-throughput drug combination screening. Using Combocat, we generate a reference dataset of over 800 unique combinations in a dense 10 × 10 matrix format across multiple cell types, and use this to train a predictive model that accurately infers drug combination effects from sparse data, drastically reducing the number of experimental measurements required. As proof of concept, we screened 9,045 combinations in a neuroblastoma cell line-the largest number of combinations tested in a single cell line to date-achieved using minimal resources. By integrating advanced drug dispensing technologies with predictive computational modeling, Combocat provides a scalable solution to accelerate the discovery of novel drug combinations.
22 April 2026 in Cancer Research
MYC is amplified on extrachromosomal DNA (ecDNA) or homogeneously staining regions (HSR) in group 3 medulloblastoma (G3-MB), conferring a poor prognosis. A better understanding of the mechanisms underlying MYC expression in ecDNA and HSRs could be leveraged to develop improved treatments for G3-MB. Using a structure–function approach, we identified and characterized an enhancer (ecMYC E1) that drives MYC activation specifically in G3-MB with MYC-amplified ecDNA or HSRs. The ecMYC E1 locus exhibited enhancer hallmarks exclusively in MYC-amplified G3-MB but not in other MYC-dependent cancer cell lines, including those with MYC amplification. Silencing of the ecMYC E1 enhancer significantly reduced MYC transcription, which was compensated for by increases in ecDNA copy number. Neuronal differentiation 1 and bromodomain-containing protein 4 interacted with each other and bound to ecMYC E1, looping the enhancer to the MYC promoter. Together, these findings define a mechanism that regulates amplified MYC gene expression within ecDNA or HSRs specifically in G3-MB. Significance: Combined structural and functional approaches identified a conserved enhancer activating MYC transcription exclusively in MYC-amplified ecDNA- and HSR-positive group 3 medulloblastoma, providing a potential therapeutic target for suppressing MYC.
4 July 2025 in NAR Genomics and Bioinformatics
Oxidative damage can introduce G>T mutations upon DNA replication. When this damage occurs ex vivo, sequenced DNA exhibits strand asymmetry, whereby sequence alignment yields G>T mismatches without corresponding C>A mismatches on the complementary strand at a given locus. Strand asymmetry is used to identify potential sequencing artefacts in somatic variant calls in cancer sequencing projects. Consistent with previous studies, we found that the strandedness of this asymmetry is frequently shared across targeted capture regions. However, while some exome sequencing datasets displayed consistent asymmetry relative to the forward reference strand, some surprisingly showed asymmetry relative to the transcription strand. Though oxidation is the principle cause of artefactual G>T mutations, we propose that the asymmetry stems from the use of single-stranded exome capture probes, as we did not find consistent asymmetry in matched whole genome sequencing. We further propose that high levels of asymmetry can be indicative of oxidation artefacts in the reported somatic variant calls of some samples. While most analysed cohorts showed low to moderate asymmetry, in one cohort (testicular germ cell tumour), approximately half of the reported G>T somatic mutations were likely to be oxidative damage artefacts, as indicated by the extent of asymmetry in mismatches and variants.